-
Rucaparib Benefits HRD-Negative Ovarian Cancer Subgroups
09 Jul 2025 07:55 GMT
Rucaparib maintenance therapy provided consistent benefits across all subgroups of … strong benefits in specific patient populations. The most pronounced benefit was … reported financial relationships with AstraZeneca, Eisai, GSK, Chugai Pharma, PharmaMar, …
-
Effects of Electroacupuncture and Mecobalamin for Utidelon-Induced Peripheral Neuropathy in Breast Cancer Patients: A Randomized Controlled Clinical Trial
15 Jul 2025 21:31 GMT
… produced by Misato Plant of Eisai Co., Ltd). They were … EA therapy possesses potential therapeutic benefits for CIPN. For instance, … suggest that EA offers benefits in improving the quality … appeared to derive more substantial benefits from EA therapies, with …
-
Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization
15 Jul 2025 12:00 GMT
… , which was originally developed by Eisai Co. Ltd. and was formerly … -specific DRP score, the therapeutic benefit rate may be enhanced. The … to derive the greatest clinical benefit from stenoparib. Allarity is headquartered …
-
First New PTSD Drug in Two Decades On the Horizon?
15 Jul 2025 08:03 GMT
… could include whether the clinical benefit is substantial enough to warrant … , Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris …
-
FDA Rejections: We Read 200 CRLs So You Don’t Have To
11 Jul 2025 14:00 GMT
… set to follow Biogen and Eisai’s rival medicine Leqembi, the … the likelihood that the clinical benefit from Vyondys 53 would be …
-
Comprehensive Lewy Body Dementia Market Analysis of Evolving Trends and Anticipated Growth Trajectory During the Forecast Period (2025-2034) | DelveInsight
11 Jul 2025 00:14 GMT
… and motor areas, with benefits increasing over six months. These … Pharma Inc., Cognition Therapeutics, Eisai Inc., Sun Pharma Advanced … key dementia companies including Eisai Co., Ltd., Eli Lilly … ., Araclon Biotech S.L., Eisai Co., Ltd., TauRx Therapeutics, …
-
Eli Lilly's Kisunla wins FDA nod for new dosing with fewer side effects in Alzheimer's
09 Jul 2025 19:24 GMT
… have an impact on the benefit-risk discussions that clinicians … ’re engaging in these benefit-risk discussions related to … because of questions surrounding their benefit-risk profiles. In March, … evaluating Kisunla’s case.
After Eisai and Biogen’s Leqembi, …
-
FDA clears new, safer regimen for Lilly's Alzheimer's drug
09 Jul 2025 20:02 GMT
… -targeting therapies like Kisunla and Eisai/Biogen's rival … lacklustre growth is that the benefits (estimated as a four- to …
-
Lilly gets FDA OK of modified dosing for Alzheimer’s drug
09 Jul 2025 16:07 GMT
… on the market, along with Eisai and Biogen’s Leqembi, both … the risk greater than the benefit, which is about a half … of delayed progression.
The risk-benefit debate has caused a regulatory … agency has said its modest benefit doesn’t justify its price …
-
US FDA approves gradual dosing for Lilly Alzheimer’s drug
09 Jul 2025 11:22 GMT
… options for patients and their benefit/risk discussions,” said Dr … ’s disease.
Kisunla competes with Eisai and Biogen’s amyloid-lowering …
About
© 1995-2025